UCLA Policy 992: Research Involving Recombinant DNA Molecules

Issuing Officer: Vice Chancellor, Research
Responsible Dept: Environment, Health & Safety
Effective Date: May 1, 1999
Supersedes: UCLA Policy 1140, dated 1/1/84

I. REFERENCES

II. BACKGROUND

As a condition for NIH funding of recombinant DNA research, the University of California, Los Angeles (UCLA) is required to ensure that such research conducted at or sponsored by UCLA, irrespective of the source of funding, complies with the NIH Guidelines. Non-compliance may result in suspension, limitation or termination of financial assistance for the non-compliant NIH-funded research projects and of NIH funds for other recombinant DNA research at UCLA. Policies and procedures have been established and implemented at UCLA to ensure that all recombinant DNA research projects are in compliance with the NIH Guidelines and that they are conducted safely.

III. STATEMENT

To ensure that all appropriate guidelines are adhered to, UCLA has established an Institutional Biosafety Committee (IBC) and has appointed a Biological Safety Officer. The IBC reviews applications for research projects involving recombinant DNA that are covered by the NIH Guidelines. Exempt experiments are not reviewed or registered. The IBC has prepared a comprehensive registration document titled, “Registration Document for Recombinant DNA and/or Infectious Agents” for completion by principal investigators when applying to conduct research involving the use of recombinant DNA (Attachment A). This form and instructions for completing it are available from the IBC, c/o Environment Health and Safety.

All research at UCLA potentially involving the use of recombinant DNA molecules and/or other infectious agents is subject to review by the IBC in accordance with the review standards contained in the NIH Guidelines. Principal Investigators are responsible for

1) determining if their experiments are covered by the NIH Guidelines, or if the experiments are exempt;
2) in the case of experiments covered by the NIH Guidelines, applying for use of recombinant DNA by completing the “Registration Document for Recombinant DNA and/or Infectious Agents” form and submitting the form to the IBC; and;
3) complying with the NIH Guidelines and applicable campus policies and procedures.

I. REFERENCES

1. Department of Health and Human Services, National Institute of Health: Guidelines for Research Involving Recombinant DNA Molecules (NIH Guidelines, the most current version).
Information about the application process or questions concerning the *NIH Guidelines* can be directed to the Biological Safety Officer at (310) 206-3929 or to: leslie@admin.ucla.edu.

IV. ATTACHMENTS

A. Registration Document for Recombinant DNA and/or Infectious Agents
   This form and instructions for completing it are available from the UCLA Institutional Biosafety Committee, c/o Environment Health and Safety.

Issuing Officer

/s/ C. Kumar Patel

Vice Chancellor, Research

Questions concerning this policy or procedure should be referred to the Responsible Department listed at the top of this document.